Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) — Capital Reinvestment Ratio
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a Capital Reinvestment Ratio of 0.33x as of December 2025, meaning it reinvests 0% of its operating cash flow ($130.31 Million) in capital expenditures ($43.17 Million). Check Amneal Pharmaceuticals, Inc. Class A Com tangible book value ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Amneal Pharmaceuticals, Inc. Class A Common Stock Capital Reinvestment Ratio (2014–2025)
This chart tracks Amneal Pharmaceuticals, Inc. Class A Common Stock's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see AMRX cash flow conversion.
Annual Capital Reinvestment Ratio for Amneal Pharmaceuticals, Inc. Class A Common Stock (2014–2025)
Year-by-year Capital Reinvestment Ratio for Amneal Pharmaceuticals, Inc. Class A Common Stock from 2014 to 2025. See AMRX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.21x | $339.99 Million | $70.06 Million | ▼ -18.9% |
| 2024 | 0.25x | $295.10 Million | $74.99 Million | ▲ +26.9% |
| 2023 | 0.20x | $345.58 Million | $69.19 Million | ▼ -85.6% |
| 2022 | 1.39x | $65.10 Million | $90.59 Million | ▲ +605.1% |
| 2021 | 0.20x | $241.82 Million | $47.73 Million | ▲ +21.0% |
| 2020 | 0.16x | $379.00 Million | $61.84 Million | ▼ -99.7% |
| 2019 | 57.14x | $1.71 Million | $97.43 Million | ▲ +14628.1% |
| 2018 | 0.39x | $250.23 Million | $97.09 Million | ▼ -20.5% |
| 2017 | 0.49x | $234.19 Million | $114.27 Million | ▼ -54.9% |
| 2016 | 1.08x | $115.06 Million | $124.61 Million | ▼ -3.2% |
| 2015 | 1.12x | $104.88 Million | $117.38 Million | ▲ +58.3% |
| 2014 | 0.71x | $112.26 Million | $79.38 Million | — |